Table 1. Open in new tab Characteristics...

Study

Design

Registration

Country

Population

Sample size

Sex (females/ males)

Age^a

Treatment arm

Treatment description

Abd-Elsalam et al. (2021)²²

Open-label, Parallel RCT

NCT04403555

Egypt

Mild/moderate COVID-19 inpatients

45/37

42.4 ± 16

IVM

IVM 12 mg/d po for 3 days + SOC

37/45

39.4 ± 16.9

SOC

Egypt Ministry of Health guidelines [paracetamol, O², fluids if needed, empiric antibiotic, oseltamivir if needed (75 mg q12h for 5 days), invasive mechanical ventilation if PaO²<60 mmHg, O² saturation <90% despite oxygen or non-invasive ventilation, progressive hypercapnia, respiratory acidosis (pH < 7.3) and progressive or refractory septic shock] for 14 days

Ahmed et al. (2021)²³

Double-blind, Parallel RCT

Bangladesh

Mild COVID-19 inpatients

37/31

42^b

IVM

IVM 12 mg/d po for 5 days

IVM + DOXY

IVM 12 mg po single dose + DOXY 200 mg on Day 1 and 100 mg q12h for 4 days

PBO

–

Babalola et al. (2021)²⁴

Double-blind, Parallel RCT

Nigeria

Asymptomatic/mild/moderate COVID-19 inpatients

6/15

48.3^b

IVM 6 mg

IVM 6 mg IV q84h for 14 days

7/14

39.7^b

IVM 12 mg

IVM 12 mg IV q84h for 14 days

6/14

44.8^b

PBO + LPV/r

PBO + LPV/r for 14 days

Camprubi et al. (2020)¹⁹

Retrospective cohort

Spain

Severe COVID-19 inpatients

4/9

43 (41–49)

IVM

IVM 200 μg/kg single dose + SOC

5/8

54 (48–58)

SOC

HCQ + AZM + supportive treatment including HFNC + LPV/r

Chaccour et al. (2021)²⁵

Double-blind, Parallel RCT

NCT04390022

Spain

Non-severe COVID-19 outpatients

5/7

26 (19–36)

IVM

IVM 400 μg/kg single dose po

7/5

26 (21–44)

PBO

–

Khan et al. (2020)²⁰

Retrospective cohort

Bangladesh

Mild/moderate COVID-19 inpatients

115

35/80

34 (30–42)

IVM

IVM 12 mg single dose within 24 h of admission + SOC

133

64/69

35 (30–45)

SOC

Antipyretics, antihistamines, antibiotics

Krolewiecki et al. (2021)²⁶

Open-label, Assessor blinded, Parallel RCT

NCT04381884

Argentina

Mild/moderate COVID-19 inpatients

15/15

42.3 ± 12.8

IVM

IVM 600 μg/kg/d po for 5 days

5/10

38.1 ± 11.7

SOC

–

López-Medina et al. (2021)²⁷

Double-blind, Parallel RCT

NCT04405843

Colombia

Mild COVID-19 patients

200

122/78

37 (29–48)

IVM

IVM 300 μg/kg/d po for 5 days

198

109/89

37 (29–49)

PBO

–

Mahmud et al. (2021)²⁸

Double-blind, Parallel RCT

NCT04523831

Bangladesh

Mild/moderate COVID-19 patients

200

77/123

41 ± 14

IVM + DOXY

IVM 12 mg single dose and DOXY 100 mg bid for 5 days + SOC

200

88/112

38 ± 12

SOC

Paracetamol, antihistamines, cough suppressants, vitamins, oxygen therapy according to indication and need, LMWH according to indication, appropriate other broad-spectrum antibiotics, remdesivir injection, other antiviral drugs and other drugs for associated comorbid conditions

Mohan et al. (2021)²⁹

Double-blind, Parallel RCT

CTRI/2020/ 06/026001

India

Mild/moderate COVID-19 inpatients

3/37

34.3 ± 10.5

IVM 24 mg

IVM 24 mg single dose po

5/35

36.3 ± 10.5

IVM 12 mg

IVM 12 mg single dose po

6/39

35.3 ± 10.5

PBO

–

Okumuş et al. (2021)³⁰

Single-blind, Parallel RCT

NCT04646109

Turkey

Severe COVID-19 inpatients

9/21

58.2 ± 11.5

IVM

IVM 200 µg/kg/d for 5 days + SOC

11/19

66.2 ± 13.3

SOC

HCQ 400 mg bid loading dose then HCQ 200 mg bid for 5 days, favipiravir 1600 mg bid loading dose then favipiravir 600 mg bid for 5 days, AZM 500 mg/d loading dose then 250 mg/d for 5 days

Pott-Junior et al. (2021)³¹

Open-label, Parallel RCT

NCT04431466

Brazil

Mild COVID-19 inpatients

4/2

50 ± 9

IVM 100 µg/kg

IVM 100 µg/kg for 7 days

5/9

49 ± 13.5

IVM 200 µg/kg

IVM 200 µg/kg for 7 days

4/3

47 ± 22.9

IVM 400 µg/kg

IVM 400 µg/kg for 7 days

4/0

54.2 ± 9.6

SOC

–

Rajter et al. (2021)²¹

Retrospective cohort

USA

COVID-19 inpatients

39/59

60.1 ± 17.4

IVM

IVM 200 µg/kg single dose po, with or without a second dose at physician discretion + SOC

39/59

59 ± 17.7

SOC

GC, HCQ, AZM

Ravikirti et al. (2021)³²

Double-blind, Parallel RCT

India

Mild/moderate COVID-19 inpatients

15/40

50.7 ± 12.7

IVM

IVM 12 mg/d for 2 days + SOC

16/41

54.2 ± 16.3

SOC

HCQ, GC, enoxaparin, antibiotics, remdesivir, convalescent plasma, tocilizumab, etc.

Shahbaznejad et al. (2021)³³

Double-blind, Parallel RCT

IRCT2011122 4008507N3

Iran

Severe COVID-19 inpatients

18/17

47.6 ± 22.2

IVM

IVM single dose, weight-adjusted dose, 3 mg for 15–24 kg, 6 mg for 25–30 kg, 9 mg for 36–50 kg, 12 mg for 51–80 kg, 0.2 mg/kg for >80 kg + SOC

18/16

45.2 ± 23.2

SOC

HCQ, CQ, LPV/r, oseltamivir, ribavirin, antibiotics (ceftriaxone, AZM, meropenem, vancomycin) and supplemental oxygen

Vallejos et al. (2021)³⁴

Double-blind, Parallel RCT

NCT04529525

Argentina

Mild/moderate COVID-19 outpatients

250

111/139

42.6 ± 15.3

IVM

IVM weight-adjusted dose, 12 mg for 2 days for ≤80 kg, 18 mg for 2 days for 81–110 kg, 24 mg for 2 days for >110 kg + SOC

251

126/125

42.4 ± 15.8

SOC

In accordance with the recommendations of the Argentine Ministry of Health

Galan et al. (2021)³⁵

Double-blind, Parallel RCT

RBR-8h7q82

Brazil

Severe COVID-19 inpatients

22/31

53.2 ± 17.3

IVM

IVM 42 mg over 4 days

25/29

54.8 ± 15.5

HCQ

HCQ 400 mg bid loading dose, then HCQ 400 mg/d for 4 days

26/35

51.9 ± 14

CQ 450 mg bid loading dose, then 450 mg/d for 4 days

Study

Design

Registration

Country

Population

Sample size

Sex (females/ males)

Age^a

Treatment arm

Treatment description

Abd-Elsalam et al. (2021)²²

Open-label, Parallel RCT

NCT04403555

Egypt

Mild/moderate COVID-19 inpatients

45/37

42.4 ± 16

IVM

IVM 12 mg/d po for 3 days + SOC

37/45

39.4 ± 16.9

SOC

Ahmed et al. (2021)²³

Double-blind, Parallel RCT

Bangladesh

Mild COVID-19 inpatients

37/31

42^b

IVM

IVM 12 mg/d po for 5 days

IVM + DOXY

IVM 12 mg po single dose + DOXY 200 mg on Day 1 and 100 mg q12h for 4 days

PBO

–

Babalola et al. (2021)²⁴

Double-blind, Parallel RCT

Nigeria

Asymptomatic/mild/moderate COVID-19 inpatients

6/15

48.3^b

IVM 6 mg

IVM 6 mg IV q84h for 14 days

7/14

39.7^b

IVM 12 mg

IVM 12 mg IV q84h for 14 days

6/14

44.8^b

PBO + LPV/r

PBO + LPV/r for 14 days

Camprubi et al. (2020)¹⁹

Retrospective cohort

Spain

Severe COVID-19 inpatients

4/9

43 (41–49)

IVM

IVM 200 μg/kg single dose + SOC

5/8

54 (48–58)

SOC

HCQ + AZM + supportive treatment including HFNC + LPV/r

Chaccour et al. (2021)²⁵

Double-blind, Parallel RCT

NCT04390022

Spain

Non-severe COVID-19 outpatients

5/7

26 (19–36)

IVM

IVM 400 μg/kg single dose po

7/5

26 (21–44)

PBO

–

Khan et al. (2020)²⁰

Retrospective cohort

Bangladesh

Mild/moderate COVID-19 inpatients

115

35/80

34 (30–42)

IVM

IVM 12 mg single dose within 24 h of admission + SOC

133

64/69

35 (30–45)

SOC

Antipyretics, antihistamines, antibiotics

Krolewiecki et al. (2021)²⁶

Open-label, Assessor blinded, Parallel RCT

NCT04381884

Argentina

Mild/moderate COVID-19 inpatients

15/15

42.3 ± 12.8

IVM

IVM 600 μg/kg/d po for 5 days

5/10

38.1 ± 11.7

SOC

–

López-Medina et al. (2021)²⁷

Double-blind, Parallel RCT

NCT04405843

Colombia

Mild COVID-19 patients

200

122/78

37 (29–48)

IVM

IVM 300 μg/kg/d po for 5 days

198

109/89

37 (29–49)

PBO

–

Mahmud et al. (2021)²⁸

Double-blind, Parallel RCT

NCT04523831

Bangladesh

Mild/moderate COVID-19 patients

200

77/123

41 ± 14

IVM + DOXY

IVM 12 mg single dose and DOXY 100 mg bid for 5 days + SOC

200

88/112

38 ± 12

SOC

Mohan et al. (2021)²⁹

Double-blind, Parallel RCT

CTRI/2020/ 06/026001

India

Mild/moderate COVID-19 inpatients

3/37

34.3 ± 10.5

IVM 24 mg

IVM 24 mg single dose po

5/35

36.3 ± 10.5

IVM 12 mg

IVM 12 mg single dose po

6/39

35.3 ± 10.5

PBO

–

Okumuş et al. (2021)³⁰

Single-blind, Parallel RCT

NCT04646109

Turkey

Severe COVID-19 inpatients

9/21

58.2 ± 11.5

IVM

IVM 200 µg/kg/d for 5 days + SOC

11/19

66.2 ± 13.3

SOC

HCQ 400 mg bid loading dose then HCQ 200 mg bid for 5 days, favipiravir 1600 mg bid loading dose then favipiravir 600 mg bid for 5 days, AZM 500 mg/d loading dose then 250 mg/d for 5 days

Pott-Junior et al. (2021)³¹

Open-label, Parallel RCT

NCT04431466

Brazil

Mild COVID-19 inpatients

4/2

50 ± 9

IVM 100 µg/kg

IVM 100 µg/kg for 7 days

5/9

49 ± 13.5

IVM 200 µg/kg

IVM 200 µg/kg for 7 days

4/3

47 ± 22.9

IVM 400 µg/kg

IVM 400 µg/kg for 7 days

4/0

54.2 ± 9.6

SOC

–

Rajter et al. (2021)²¹

Retrospective cohort

USA

COVID-19 inpatients

39/59

60.1 ± 17.4

IVM

IVM 200 µg/kg single dose po, with or without a second dose at physician discretion + SOC

39/59

59 ± 17.7

SOC

GC, HCQ, AZM

Ravikirti et al. (2021)³²

Double-blind, Parallel RCT

India

Mild/moderate COVID-19 inpatients

15/40

50.7 ± 12.7

IVM

IVM 12 mg/d for 2 days + SOC

16/41

54.2 ± 16.3

SOC

HCQ, GC, enoxaparin, antibiotics, remdesivir, convalescent plasma, tocilizumab, etc.

Shahbaznejad et al. (2021)³³

Double-blind, Parallel RCT

IRCT2011122 4008507N3

Iran

Severe COVID-19 inpatients

18/17

47.6 ± 22.2

IVM

IVM single dose, weight-adjusted dose, 3 mg for 15–24 kg, 6 mg for 25–30 kg, 9 mg for 36–50 kg, 12 mg for 51–80 kg, 0.2 mg/kg for >80 kg + SOC

18/16

45.2 ± 23.2

SOC

HCQ, CQ, LPV/r, oseltamivir, ribavirin, antibiotics (ceftriaxone, AZM, meropenem, vancomycin) and supplemental oxygen

Vallejos et al. (2021)³⁴

Double-blind, Parallel RCT

NCT04529525

Argentina

Mild/moderate COVID-19 outpatients

250

111/139

42.6 ± 15.3

IVM

IVM weight-adjusted dose, 12 mg for 2 days for ≤80 kg, 18 mg for 2 days for 81–110 kg, 24 mg for 2 days for >110 kg + SOC

251

126/125

42.4 ± 15.8

SOC

In accordance with the recommendations of the Argentine Ministry of Health

Galan et al. (2021)³⁵

Double-blind, Parallel RCT

RBR-8h7q82

Brazil

Severe COVID-19 inpatients

22/31

53.2 ± 17.3

IVM

IVM 42 mg over 4 days

25/29

54.8 ± 15.5

HCQ

HCQ 400 mg bid loading dose, then HCQ 400 mg/d for 4 days

26/35

51.9 ± 14

CQ 450 mg bid loading dose, then 450 mg/d for 4 days

Table 1.

Open in new tab

Characteristics of included studies and patients

Study	Design	Registration	Country	Population	Sample size	Sex (females/ males)	Age^a	Treatment arm	Treatment description
Abd-Elsalam et al. (2021)²²	Open-label, Parallel RCT	NCT04403555	Egypt	Mild/moderate COVID-19 inpatients	82	45/37	42.4 ± 16	IVM	IVM 12 mg/d po for 3 days + SOC
Abd-Elsalam et al. (2021)²²	Open-label, Parallel RCT	NCT04403555	Egypt	Mild/moderate COVID-19 inpatients	82	37/45	39.4 ± 16.9	SOC	Egypt Ministry of Health guidelines [paracetamol, O², fluids if needed, empiric antibiotic, oseltamivir if needed (75 mg q12h for 5 days), invasive mechanical ventilation if PaO²<60 mmHg, O² saturation <90% despite oxygen or non-invasive ventilation, progressive hypercapnia, respiratory acidosis (pH < 7.3) and progressive or refractory septic shock] for 14 days
Ahmed et al. (2021)²³	Double-blind, Parallel RCT	-	Bangladesh	Mild COVID-19 inpatients	22	37/31	42^b	IVM	IVM 12 mg/d po for 5 days
					23			IVM + DOXY	IVM 12 mg po single dose + DOXY 200 mg on Day 1 and 100 mg q12h for 4 days
					23			PBO	–
Babalola et al. (2021)²⁴	Double-blind, Parallel RCT	-	Nigeria	Asymptomatic/mild/moderate COVID-19 inpatients	21	6/15	48.3^b	IVM 6 mg	IVM 6 mg IV q84h for 14 days
					21	7/14	39.7^b	IVM 12 mg	IVM 12 mg IV q84h for 14 days
					20	6/14	44.8^b	PBO + LPV/r	PBO + LPV/r for 14 days
Camprubi et al. (2020)¹⁹	Retrospective cohort	-	Spain	Severe COVID-19 inpatients	13	4/9	43 (41–49)	IVM	IVM 200 μg/kg single dose + SOC
Camprubi et al. (2020)¹⁹	Retrospective cohort	-	Spain	Severe COVID-19 inpatients	13	5/8	54 (48–58)	SOC	HCQ + AZM + supportive treatment including HFNC + LPV/r
Chaccour et al. (2021)²⁵	Double-blind, Parallel RCT	NCT04390022	Spain	Non-severe COVID-19 outpatients	12	5/7	26 (19–36)	IVM	IVM 400 μg/kg single dose po
Chaccour et al. (2021)²⁵	Double-blind, Parallel RCT	NCT04390022	Spain	Non-severe COVID-19 outpatients	12	7/5	26 (21–44)	PBO	–
Khan et al. (2020)²⁰	Retrospective cohort	-	Bangladesh	Mild/moderate COVID-19 inpatients	115	35/80	34 (30–42)	IVM	IVM 12 mg single dose within 24 h of admission + SOC
Khan et al. (2020)²⁰	Retrospective cohort	-	Bangladesh	Mild/moderate COVID-19 inpatients	133	64/69	35 (30–45)	SOC	Antipyretics, antihistamines, antibiotics
Krolewiecki et al. (2021)²⁶	Open-label, Assessor blinded, Parallel RCT	NCT04381884	Argentina	Mild/moderate COVID-19 inpatients	30	15/15	42.3 ± 12.8	IVM	IVM 600 μg/kg/d po for 5 days
Krolewiecki et al. (2021)²⁶	Open-label, Assessor blinded, Parallel RCT	NCT04381884	Argentina	Mild/moderate COVID-19 inpatients	15	5/10	38.1 ± 11.7	SOC	–
López-Medina et al. (2021)²⁷	Double-blind, Parallel RCT	NCT04405843	Colombia	Mild COVID-19 patients	200	122/78	37 (29–48)	IVM	IVM 300 μg/kg/d po for 5 days
López-Medina et al. (2021)²⁷	Double-blind, Parallel RCT	NCT04405843	Colombia	Mild COVID-19 patients	198	109/89	37 (29–49)	PBO	–
Mahmud et al. (2021)²⁸	Double-blind, Parallel RCT	NCT04523831	Bangladesh	Mild/moderate COVID-19 patients	200	77/123	41 ± 14	IVM + DOXY	IVM 12 mg single dose and DOXY 100 mg bid for 5 days + SOC
Mahmud et al. (2021)²⁸	Double-blind, Parallel RCT	NCT04523831	Bangladesh	Mild/moderate COVID-19 patients	200	88/112	38 ± 12	SOC	Paracetamol, antihistamines, cough suppressants, vitamins, oxygen therapy according to indication and need, LMWH according to indication, appropriate other broad-spectrum antibiotics, remdesivir injection, other antiviral drugs and other drugs for associated comorbid conditions
Mohan et al. (2021)²⁹	Double-blind, Parallel RCT	CTRI/2020/ 06/026001	India	Mild/moderate COVID-19 inpatients	40	3/37	34.3 ± 10.5	IVM 24 mg	IVM 24 mg single dose po
					40	5/35	36.3 ± 10.5	IVM 12 mg	IVM 12 mg single dose po
					45	6/39	35.3 ± 10.5	PBO	–
Okumuş et al. (2021)³⁰	Single-blind, Parallel RCT	NCT04646109	Turkey	Severe COVID-19 inpatients	30	9/21	58.2 ± 11.5	IVM	IVM 200 µg/kg/d for 5 days + SOC
Okumuş et al. (2021)³⁰	Single-blind, Parallel RCT	NCT04646109	Turkey	Severe COVID-19 inpatients	30	11/19	66.2 ± 13.3	SOC	HCQ 400 mg bid loading dose then HCQ 200 mg bid for 5 days, favipiravir 1600 mg bid loading dose then favipiravir 600 mg bid for 5 days, AZM 500 mg/d loading dose then 250 mg/d for 5 days
Pott-Junior et al. (2021)³¹	Open-label, Parallel RCT	NCT04431466	Brazil	Mild COVID-19 inpatients	6	4/2	50 ± 9	IVM 100 µg/kg	IVM 100 µg/kg for 7 days
					14	5/9	49 ± 13.5	IVM 200 µg/kg	IVM 200 µg/kg for 7 days
					7	4/3	47 ± 22.9	IVM 400 µg/kg	IVM 400 µg/kg for 7 days
					4	4/0	54.2 ± 9.6	SOC	–
Rajter et al. (2021)²¹	Retrospective cohort	-	USA	COVID-19 inpatients	98	39/59	60.1 ± 17.4	IVM	IVM 200 µg/kg single dose po, with or without a second dose at physician discretion + SOC
Rajter et al. (2021)²¹	Retrospective cohort	-	USA	COVID-19 inpatients	98	39/59	59 ± 17.7	SOC	GC, HCQ, AZM
Ravikirti et al. (2021)³²	Double-blind, Parallel RCT	-	India	Mild/moderate COVID-19 inpatients	55	15/40	50.7 ± 12.7	IVM	IVM 12 mg/d for 2 days + SOC
Ravikirti et al. (2021)³²	Double-blind, Parallel RCT	-	India	Mild/moderate COVID-19 inpatients	57	16/41	54.2 ± 16.3	SOC	HCQ, GC, enoxaparin, antibiotics, remdesivir, convalescent plasma, tocilizumab, etc.
Shahbaznejad et al. (2021)³³	Double-blind, Parallel RCT	IRCT2011122 4008507N3	Iran	Severe COVID-19 inpatients	35	18/17	47.6 ± 22.2	IVM	IVM single dose, weight-adjusted dose, 3 mg for 15–24 kg, 6 mg for 25–30 kg, 9 mg for 36–50 kg, 12 mg for 51–80 kg, 0.2 mg/kg for >80 kg + SOC
Shahbaznejad et al. (2021)³³	Double-blind, Parallel RCT	IRCT2011122 4008507N3	Iran	Severe COVID-19 inpatients	34	18/16	45.2 ± 23.2	SOC	HCQ, CQ, LPV/r, oseltamivir, ribavirin, antibiotics (ceftriaxone, AZM, meropenem, vancomycin) and supplemental oxygen
Vallejos et al. (2021)³⁴	Double-blind, Parallel RCT	NCT04529525	Argentina	Mild/moderate COVID-19 outpatients	250	111/139	42.6 ± 15.3	IVM	IVM weight-adjusted dose, 12 mg for 2 days for ≤80 kg, 18 mg for 2 days for 81–110 kg, 24 mg for 2 days for >110 kg + SOC
Vallejos et al. (2021)³⁴	Double-blind, Parallel RCT	NCT04529525	Argentina	Mild/moderate COVID-19 outpatients	251	126/125	42.4 ± 15.8	SOC	In accordance with the recommendations of the Argentine Ministry of Health
Galan et al. (2021)³⁵	Double-blind, Parallel RCT	RBR-8h7q82	Brazil	Severe COVID-19 inpatients	53	22/31	53.2 ± 17.3	IVM	IVM 42 mg over 4 days
					54	25/29	54.8 ± 15.5	HCQ	HCQ 400 mg bid loading dose, then HCQ 400 mg/d for 4 days
					61	26/35	51.9 ± 14	CQ	CQ 450 mg bid loading dose, then 450 mg/d for 4 days

Study	Design	Registration	Country	Population	Sample size	Sex (females/ males)	Age^a	Treatment arm	Treatment description
Abd-Elsalam et al. (2021)²²	Open-label, Parallel RCT	NCT04403555	Egypt	Mild/moderate COVID-19 inpatients	82	45/37	42.4 ± 16	IVM	IVM 12 mg/d po for 3 days + SOC
Abd-Elsalam et al. (2021)²²	Open-label, Parallel RCT	NCT04403555	Egypt	Mild/moderate COVID-19 inpatients	82	37/45	39.4 ± 16.9	SOC	Egypt Ministry of Health guidelines [paracetamol, O², fluids if needed, empiric antibiotic, oseltamivir if needed (75 mg q12h for 5 days), invasive mechanical ventilation if PaO²<60 mmHg, O² saturation <90% despite oxygen or non-invasive ventilation, progressive hypercapnia, respiratory acidosis (pH < 7.3) and progressive or refractory septic shock] for 14 days
Ahmed et al. (2021)²³	Double-blind, Parallel RCT	-	Bangladesh	Mild COVID-19 inpatients	22	37/31	42^b	IVM	IVM 12 mg/d po for 5 days
					23			IVM + DOXY	IVM 12 mg po single dose + DOXY 200 mg on Day 1 and 100 mg q12h for 4 days
					23			PBO	–
Babalola et al. (2021)²⁴	Double-blind, Parallel RCT	-	Nigeria	Asymptomatic/mild/moderate COVID-19 inpatients	21	6/15	48.3^b	IVM 6 mg	IVM 6 mg IV q84h for 14 days
					21	7/14	39.7^b	IVM 12 mg	IVM 12 mg IV q84h for 14 days
					20	6/14	44.8^b	PBO + LPV/r	PBO + LPV/r for 14 days
Camprubi et al. (2020)¹⁹	Retrospective cohort	-	Spain	Severe COVID-19 inpatients	13	4/9	43 (41–49)	IVM	IVM 200 μg/kg single dose + SOC
Camprubi et al. (2020)¹⁹	Retrospective cohort	-	Spain	Severe COVID-19 inpatients	13	5/8	54 (48–58)	SOC	HCQ + AZM + supportive treatment including HFNC + LPV/r
Chaccour et al. (2021)²⁵	Double-blind, Parallel RCT	NCT04390022	Spain	Non-severe COVID-19 outpatients	12	5/7	26 (19–36)	IVM	IVM 400 μg/kg single dose po
Chaccour et al. (2021)²⁵	Double-blind, Parallel RCT	NCT04390022	Spain	Non-severe COVID-19 outpatients	12	7/5	26 (21–44)	PBO	–
Khan et al. (2020)²⁰	Retrospective cohort	-	Bangladesh	Mild/moderate COVID-19 inpatients	115	35/80	34 (30–42)	IVM	IVM 12 mg single dose within 24 h of admission + SOC
Khan et al. (2020)²⁰	Retrospective cohort	-	Bangladesh	Mild/moderate COVID-19 inpatients	133	64/69	35 (30–45)	SOC	Antipyretics, antihistamines, antibiotics
Krolewiecki et al. (2021)²⁶	Open-label, Assessor blinded, Parallel RCT	NCT04381884	Argentina	Mild/moderate COVID-19 inpatients	30	15/15	42.3 ± 12.8	IVM	IVM 600 μg/kg/d po for 5 days
Krolewiecki et al. (2021)²⁶	Open-label, Assessor blinded, Parallel RCT	NCT04381884	Argentina	Mild/moderate COVID-19 inpatients	15	5/10	38.1 ± 11.7	SOC	–
López-Medina et al. (2021)²⁷	Double-blind, Parallel RCT	NCT04405843	Colombia	Mild COVID-19 patients	200	122/78	37 (29–48)	IVM	IVM 300 μg/kg/d po for 5 days
López-Medina et al. (2021)²⁷	Double-blind, Parallel RCT	NCT04405843	Colombia	Mild COVID-19 patients	198	109/89	37 (29–49)	PBO	–
Mahmud et al. (2021)²⁸	Double-blind, Parallel RCT	NCT04523831	Bangladesh	Mild/moderate COVID-19 patients	200	77/123	41 ± 14	IVM + DOXY	IVM 12 mg single dose and DOXY 100 mg bid for 5 days + SOC
Mahmud et al. (2021)²⁸	Double-blind, Parallel RCT	NCT04523831	Bangladesh	Mild/moderate COVID-19 patients	200	88/112	38 ± 12	SOC	Paracetamol, antihistamines, cough suppressants, vitamins, oxygen therapy according to indication and need, LMWH according to indication, appropriate other broad-spectrum antibiotics, remdesivir injection, other antiviral drugs and other drugs for associated comorbid conditions
Mohan et al. (2021)²⁹	Double-blind, Parallel RCT	CTRI/2020/ 06/026001	India	Mild/moderate COVID-19 inpatients	40	3/37	34.3 ± 10.5	IVM 24 mg	IVM 24 mg single dose po
					40	5/35	36.3 ± 10.5	IVM 12 mg	IVM 12 mg single dose po
					45	6/39	35.3 ± 10.5	PBO	–
Okumuş et al. (2021)³⁰	Single-blind, Parallel RCT	NCT04646109	Turkey	Severe COVID-19 inpatients	30	9/21	58.2 ± 11.5	IVM	IVM 200 µg/kg/d for 5 days + SOC
Okumuş et al. (2021)³⁰	Single-blind, Parallel RCT	NCT04646109	Turkey	Severe COVID-19 inpatients	30	11/19	66.2 ± 13.3	SOC	HCQ 400 mg bid loading dose then HCQ 200 mg bid for 5 days, favipiravir 1600 mg bid loading dose then favipiravir 600 mg bid for 5 days, AZM 500 mg/d loading dose then 250 mg/d for 5 days
Pott-Junior et al. (2021)³¹	Open-label, Parallel RCT	NCT04431466	Brazil	Mild COVID-19 inpatients	6	4/2	50 ± 9	IVM 100 µg/kg	IVM 100 µg/kg for 7 days
					14	5/9	49 ± 13.5	IVM 200 µg/kg	IVM 200 µg/kg for 7 days
					7	4/3	47 ± 22.9	IVM 400 µg/kg	IVM 400 µg/kg for 7 days
					4	4/0	54.2 ± 9.6	SOC	–
Rajter et al. (2021)²¹	Retrospective cohort	-	USA	COVID-19 inpatients	98	39/59	60.1 ± 17.4	IVM	IVM 200 µg/kg single dose po, with or without a second dose at physician discretion + SOC
Rajter et al. (2021)²¹	Retrospective cohort	-	USA	COVID-19 inpatients	98	39/59	59 ± 17.7	SOC	GC, HCQ, AZM
Ravikirti et al. (2021)³²	Double-blind, Parallel RCT	-	India	Mild/moderate COVID-19 inpatients	55	15/40	50.7 ± 12.7	IVM	IVM 12 mg/d for 2 days + SOC
Ravikirti et al. (2021)³²	Double-blind, Parallel RCT	-	India	Mild/moderate COVID-19 inpatients	57	16/41	54.2 ± 16.3	SOC	HCQ, GC, enoxaparin, antibiotics, remdesivir, convalescent plasma, tocilizumab, etc.
Shahbaznejad et al. (2021)³³	Double-blind, Parallel RCT	IRCT2011122 4008507N3	Iran	Severe COVID-19 inpatients	35	18/17	47.6 ± 22.2	IVM	IVM single dose, weight-adjusted dose, 3 mg for 15–24 kg, 6 mg for 25–30 kg, 9 mg for 36–50 kg, 12 mg for 51–80 kg, 0.2 mg/kg for >80 kg + SOC
Shahbaznejad et al. (2021)³³	Double-blind, Parallel RCT	IRCT2011122 4008507N3	Iran	Severe COVID-19 inpatients	34	18/16	45.2 ± 23.2	SOC	HCQ, CQ, LPV/r, oseltamivir, ribavirin, antibiotics (ceftriaxone, AZM, meropenem, vancomycin) and supplemental oxygen
Vallejos et al. (2021)³⁴	Double-blind, Parallel RCT	NCT04529525	Argentina	Mild/moderate COVID-19 outpatients	250	111/139	42.6 ± 15.3	IVM	IVM weight-adjusted dose, 12 mg for 2 days for ≤80 kg, 18 mg for 2 days for 81–110 kg, 24 mg for 2 days for >110 kg + SOC
Vallejos et al. (2021)³⁴	Double-blind, Parallel RCT	NCT04529525	Argentina	Mild/moderate COVID-19 outpatients	251	126/125	42.4 ± 15.8	SOC	In accordance with the recommendations of the Argentine Ministry of Health
Galan et al. (2021)³⁵	Double-blind, Parallel RCT	RBR-8h7q82	Brazil	Severe COVID-19 inpatients	53	22/31	53.2 ± 17.3	IVM	IVM 42 mg over 4 days
					54	25/29	54.8 ± 15.5	HCQ	HCQ 400 mg bid loading dose, then HCQ 400 mg/d for 4 days
					61	26/35	51.9 ± 14	CQ	CQ 450 mg bid loading dose, then 450 mg/d for 4 days

Cells containing ‘-’ indicate that no relevant data were reported.

RCT, randomized controlled trial; SOC, standard of care; LPV/r: lopinavir–ritonavir combination therapy; IVM, ivermectin; DOXY, doxycycline; PBO, placebo; HCQ, hydroxychloroquine; AZM, azithromycin; HFNC, high flow nasal cannula; LMWH, low molecular weight heparin; GC, glucocorticoid; CQ, chloroquine; SD, standard deviation; IQR, interquartile range.

Age is presented as mean (SD) or median (IQR) unless otherwise specified.

Only the mean age was reported with no variance.

This Feature Is Available To Subscribers Only